Skip to main content
. 2017 Jun 12;8(30):50002–50014. doi: 10.18632/oncotarget.18442

Figure 5. Effect of ERβ agonist Liq on OCa progression in vivo.

Figure 5

(A) Athymic nude mice were implanted with SKOV3ip1-Luc cells intra-peritoneally and treated with vehicle or Liq for 3 weeks. Luciferase intensity detected by the Xenogen in vivo imaging system was used to measure tumor growth. (B) Representative images of tumor-bearing mice from control and treatment groups are shown. The tumor weight (C) and number of nodules (D) from control and treatment group are shown. Ki67 expression (E) as a marker of proliferation and TUNEL staining (F) as a marker of apoptosis were analyzed by performing immunohistochemistry (IHC) on tumor sections. For quantitation, Ki-67-positive and apoptotic cells from five different fields were counted and plotted as histogram. Data are represented as mean ± SE. * p<0.05. **p<0.01. (G) The expression of NF-κB target genes IL-1 beta and Cox-2 was determined on vehicle or Liq treated tumor sections by performing IHC.